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Abstract
Background: Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in
development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid
β (Aβ) protofibrils.
Methods: Here we describe the first clinical study with BAN2401. Safety and tolerability were investigated in
mild to moderate AD. A study design was used with staggered parallel single and multiple ascending doses,
from 0.1 mg/kg as a single dose to 10 mg/kg biweekly for four months. The presence of amyloid related
imaging abnormalities (ARIA, E for edema, H for hemorrhage) was assessed with magnetic resonance imaging
(MRI). Cerebrospinal fluid (CSF) and plasma samples were analyzed to investigate pharmacokinetics (PK) and
effects on biomarkers.
Results: The incidence of ARIA-E/H on MRI was comparable to that of placebo. BAN2401 exposure was approximately
dose proportional, with a serum terminal elimination half-life of ~7 days. Only a slight increase of plasma Aβ(1-40) was
observed but there were no measurable effects of BAN2401 on CSF biomarkers. On the basis of these findings Phase
2b efficacy study has been initiated in early AD.
Conclusions: BAN2401 was well-tolerated across all doses. The PK profile has guided us for selecting dose and
dose regimens in the ongoing phase 2b study. There was no clear guidance for an effective dose based on
biomarkers.
Trial registration number: NCT01230853 ClinicalTrials.gov Registered October 27, 2010.
Keywords: Alzheimer's disease, Amyloid-β, Aβ, Protofibril, Immunotherapy, BAN2401, mAb158, ARIA,
Clinical trial
Background
Current treatments for Alzheimer’s disease (AD) have
no effect on disease progression, which creates a large
unmet medical need. Several monoclonal antibodies
against amyloid β (Aβ) are in development as potential
disease-modifying treatments. Antibodies are attractive
drugs as they can be made highly specific for their tar-
get. Data from recent AD trials remain inconclusive, but
provide some suggestion that a treatment effect of im-
munotherapy is possible. Bapineuzumab, a monoclonal
antibody targeting non-selectively all forms of Aβ, gener-
ated side-effects leading to lowering of treatment doses
and no treatment effect was found [12]. Solanezumab
was developed to target soluble, monomeric Aβ. In two
phase 3 studies, solanezumab did not meet primary end-
points [2]. However, when data from the two studies
were pooled, a pattern emerged with a slowing of cogni-
tive decline in the subgroup of mild AD. The lack of ro-
bust clinical effect with antibodies binding Aβ fibrils or
monomers has drawn attention to antibodies targeting
soluble, aggregated forms of Aβ.
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Aβ exists in various conformational states - mono-
mers, oligomers, protofibrils, and insoluble fibrils
[10, 11, 22]. Protofibrils are soluble Aβ aggregates,
larger than approximately 100 kDa, i. e., eluting in
the void volume on a Size Exclusion Superdex 75
column [1, 8, 9, 19, 20]. There is increasing evidence
suggesting that oligomers and protofibrils are more
toxic than insoluble fibrils or monomers and that
they mediate neurotoxicity and alter synaptic func-
tion [7, 10, 21, 22]. The Arctic Alzheimer mutation
(AβPP E693G) has been shown to specifically in-
crease the formation of soluble Aβ protofibrils, an
Aβ species toxic to neurons and likely to be present
in all cases of AD [9]. Indeed, Arctic mutation cases
were negative for fibrillar amyloid, as measured by
Pittsburg compound B (11C-PIB) with positron emis-
sion tomography (PET) [13]. This suggests that re-
ducing Aβ protofibrils could provide an effective
treatment approach for AD that might ameliorate
neuronal toxicity and potentially improve other
pathological processes, e.g., synaptic dysfunction, in-
flammatory changes, and, ultimately, neuronal loss
[4, 5, 10].
mAb158 is a murine monoclonal antibody that was
raised to target protofibrils [3], and BAN2401 is the hu-
manized IgG1 monoclonal version that selectively binds
to Aβ protofibrils. In vitro studies demonstrated that the
binding characteristics are essentially indistinguishable
from mAb158. BAN2401 has at least a 1000-fold higher
selectivity for protofibrils compared to monomers and
10-15 times better binding to protofibrils than to fibrils
[14, 15]. Treatment of transgenic mice carrying both the
Swedish and the Arctic mutations with mAb158 demon-
strated that plaque formation was prevented if the anti-
body was given before the appearance of plaque in
young mice. If treatment started later in this mouse
model, levels of insoluble Aβ in the brains of plaque-
bearing old mice were not affected. However, in both
cases, soluble Aβ protofibril levels were diminished,
showing that mAb158 can selectively reduce protofibrils
in vivo [6].
The objectives of this study were to evaluate the safety
and tolerability of BAN2401 in AD patients following
single and multiple ascending doses and to assess the
pharmacokinetics (PK) in serum and cerebrospinal fluid
(CSF). In addition, effects of BAN2401 on CSF and
plasma biomarkers of AD were investigated.
Methods
Study design
A multicenter double-blind randomized placebo-controlled
study was performed in subjects with mild to moderate
AD. No major issues in our animal studies, or in the formal
toxicological studies were seen. The starting dose was set
with an acceptable margin to NOAEL (No Observed
Adverse Effect Level). Estimations of dose levels were made
from treatment studies in our transgenic Alzheimer mice
models. The top dose was chosen from our studies on
transgenic Alzheimer mice and based on lowering of Aβ
protofibrils.
The study was comprised of two parts. In the single
ascending dose (SAD) study, doses of 0.1, 0.3, 1, 3, 10,
and 15 mg/kg were evaluated. A multiple ascending dose
(MAD) part investigated doses of 0.3, 1, and 3 mg/kg ad-
ministered every four weeks with a total of four doses
over four months and a dose of 10 mg/kg biweekly, with
a total of seven doses over four months (Fig. 1). Each co-
hort consisted of eight subjects, two randomized to placebo
and six to BAN2401. BAN2401 was given as an i. v. infu-
sion. Treatment periods of the SAD and MAD cohorts
took place in a staggered parallel manner. Cohorts were
initiated after review of the safety and PK data of the
previous cohorts. Before determining to proceed to the
next dose level, each SAD cohort was observed for four
weeks post dose. This included assessment of a non-
contrast brain MRI at three weeks after dosing to
evaluate the presence of amyloid related imaging ab-
normalities (ARIA-E for edema/H for hemorrhage).
Treatment in each MAD cohort was initiated after re-
view of all available safety data, including data from the
equivalent and the next higher single dose levels. Data
included MRI, vital signs, electrocardiogram (ECG) and
laboratory data collected at least three weeks post dose
in the SAD study. Subjects were followed for up to
180 days after final dosing.
The study was carried out in accordance with the prin-
ciples of the Declaration of Helsinki and Good Clinical
Practice guidelines and was in full compliance with
International Conference on Harmonisation guidelines
and all applicable local good clinical practice regulations.
Fig. 1 Study design with overlapping SAD-MAD cohorts, where
treatment periods took place in a staggered parallel manner. A
cohort was initiated after review of the safety and PK data of the
previous cohorts. SAD single ascending dose, MAD multiple ascending
dose, PK pharmacokinetics
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Table 1 Subject demographics percentages are based on the total number of subjects with nonmissing values in relevant treatment group
SAD study MAD study
Placebo BAN2401 (mg/kg) Placebo BAN2401 (mg/kg)
(N = 12) 0.1 (N = 6) 0.3 (N = 6) 1 (N = 6) 3 (N = 6) 10 (N = 6) 15 (N = 6) Total (N = 36) (N = 8) 0.3 (N = 6) 1 (N = 6) 3 (N = 6) 10 (N = 6) Total (N = 24)
Age: mean year (SD) 72.1 (9.2) 70.0 (12.0) 72.7 (6.5) 75.0 (14.0) 68.2 (8.4) 68.7 (9.1) 70.8 (11.5) 70.9 (10.0) 70.0 (11.70) 69.0 (13.19) 69.0 (6.99) 71.8 (11.48) 70.3 (9.81) 70.0 (9.97)
Female gender, n (%) 5 (41.7) 4 (66.7) 2 (33.3) 2 (33.3) 3 (50.0) 2 (33.3) 5 (83.3) 18 (50.0) 2 (25.0) 2 (33.3) 5 (83.3) 4 (66.7) 2 (33.3) 13 (54.2)
MMSE (mean) 23.5 25.2 24.7 23.5 24.0 24.2 21.5 23.8 24.1 24.0 21.7 23.7 23.8 23.3















Eligible subjects were aged ≥50 years with mild to mod-
erate AD, according to National Institute of Neurological
and Communicative Disorders and Stroke and the Alz-
heimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria and Mini Mental State
Examination (MMSE) scores of 16-28. Subjects receiving
symptomatic treatment for AD were required to have
been on stable doses for at least 12 weeks prior to Base-
line visit.
Safety
Safety assessments for SAD, MAD1-3, and MAD4 are out-
lined in Additional file 1: Addendum, Tables S1A-S3A, re-
spectively. To assess for ARIA, regular non-contrast brain
MRI scans were performed to detect ARIA-H [18] accord-
ing to the schedule outlined in Additional file 1: Tables
S1A-S3A. All subjects underwent MRI at baseline. Subse-
quent MRI scans were performed at three weeks, three
months, and at the termination visit at 180 days post dose
for SAD1-5 and at 90 days for SAD6. Doses were not ad-
ministered until evaluation of the most recent MRI. An
additional safety MRI was conducted at 90 and 180 days
after the final dose for MAD1 and MAD2 cohorts, and at
90 days for MAD3 and MAD4 cohorts.
Pharmacokinetics
In the SAD cohorts, serum concentrations of BAN2401
were measured pre dose, at 0, 0.5, 1, 2, 4, 8, and 24 h
post dose, and at 10, 21, 28, 90 and 180 days post dose.
Concentrations of BAN2401 in CSF were measured in
SAD6 (15 mg/kg) on day 2 for the first four subjects and
on day 10 for the next four subjects. In the MAD co-
horts, serum BAN2401 concentrations were measured
pre dose and immediately post dose for all four infu-
sions. Additional samples were collected at 0.5, 1, 2, 4, 8,
and 24 h post dose after doses 1 and 4. In addition, sin-
gle samples were collected three weeks and three
months post dose. A validated method for measurement
of BAN2401 based on liquid chromatography and mass
spectrometry (LCMS) (Frontage Laboratories, Exon, PA,
USA) was used. The LCMS method had a lower limit
of quantification of 0.5 μg/mL. Concentrations of
BAN2401 in CSF were measured using a validated
ELISA with electrochemiluminence detection with a
lower limit of quantification of 3 ng/mL.
Target engagement and pharmacodynamics
Plasma concentrations of Aβ(1-40) were measured at the
same time points as for the PK assessments. It was not
possible to measure reliably plasma Aβ(1-42) due to
technical difficulties. Evidence for a dose relationship
with plasma biomarkers was evaluated. Aβ(1-42), t-tau,
and p-tau concentrations were measured in the CSF
collected at baseline and in SAD6 and MAD4 10-14
days after the final dose in each cohort. All statistics
were descriptive.
Ethical approval
Ethical approvals were obtained from Copernikus Group
IRB, 1 Triangle Drive, #100, Research Triangle Park, NC
27709, Veterans Administration Long Beach Health
Care, System IRB, MC 09-151, 5901 East 7th Street,
Long Beach, CA 90822, and Research Compliance
Administration, IUPUI 980 Indiana Avenue, Room 3315
Indianapolis, IN 46202. Informed consent was obtained
from all patients participating in the trial.
Results
Subjects
Participant demographics are shown in Table 1. Mean
age of the 48 subjects in the SAD cohorts was 70.9 years
and mean MMSE score was 23.8. For the 32 subjects in
the MAD cohorts, the mean age was 70.0 years and the
mean MMSE score was 23.3. Overall, demographic and
other baseline characteristics of the groups treated with
BAN2401 were similar to those of subjects on placebo.
Subject disposition is shown in Fig. 2.
Safety
The numbers of subjects experiencing treatment emergent
adverse events (TEAEs) are shown in Tables 2 and 3. There
were no trends to suggest an increasing incidence of TEAEs
with increasing dose across the SAD cohorts. All of the
TEAEs were classified as mild or moderate. The most fre-
quently observed TEAEs with a single dose of BAN2401
were dizziness (8.3 vs. 8.3 % on placebo), fatigue (5.6 vs
8.3 % on placebo), and sinusitis (5.6 vs 0 % on placebo).
One subject on BAN2401 in the 0.3 mg/kg SAD co-
hort developed new asymptomatic ARIA-H during treat-
ment. The subject had two microhemorrhages at
baseline and developed new asymptomatic ARIA-Hs
identified on routine MRI on Days 90 and 180. The sub-
ject remained clinically stable throughout the study.
Fig. 2 Patient disposition. SAD single ascending dose, MAD multiple
ascending dose
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One subject on BAN2401 in the 1 mg/kg SAD cohort
experienced an asymptomatic ARIA-H, discovered on
Day 21 routine MRI scan considered by the investigator
to be possibly related to the study drug. This macrohe-
morrhage was just above the upper size limit of micro-
hemorrhages. The subject remained asymptomatic
throughout the study, and the ARIA-H had completely
resolved by Day 180. There was one case initially inter-
preted as vasogenic edema in a subject on active drug in
the 3 mg/kg SAD cohort. However, this was not consid-
ered study related as it was associated with a brain nod-
ule secondary to metastasis from a primary lung tumor,
present prior to the initiation of treatment.
The most frequently observed TEAEs in subjects
treated with multiple doses of BAN2401 were upper re-
spiratory tract infection (16.7 vs. 12.5 % on placebo),
headache (12.5 vs. 25 % on placebo), and orthostatic
hypotension (12.5 vs. 0 % on placebo) (Tables 2 and 3).
All of the TEAEs were classified as mild or moderate
with no severe TEAEs.
Six subjects in the MAD cohorts, of which one was
on placebo, had ARIA-Hs detected by MRI at
baseline. In the 1 mg/kg MAD cohort, new asymp-
tomatic ARIA-Hs emerged during the study in the
two subjects on placebo and in one subject on active
treatment. The subject on BAN2401 (1 mg/kg) had
two new ARIA-Hs identified on MRI after three
doses. All three of these subjects remained clinically
stable throughout the study. No new abnormal neuro-
logical or MRI findings associated with these ARIA-
Es were observed.
Over the course of the entire study there were no
symptomatic ARIA-Es, ARIA-Es or superficial hemosi-
derosis seen with either single or multiple BAN2401
doses. No subject experienced a TEAE that resulted in
discontinuation or death.
The incidence of treatment-emergent, out-of-range
values in hematology, clinical chemistry, or urinalysis
parameters was comparable between different doses of
BAN2401 and placebo throughout the treatment
period. The mean values of vital signs in subjects
treated with various BAN2401 doses were generally
stable and comparable to those on placebo throughout
the treatment period.
Table 3 Adverse events in MAD cohorts. Those TEAEs that occurred in more than one cohort in the MAD study are listed
MedDRA Preferred Term Placebo BAN2401 (mg/kg)
(N = 12) (%) 0.3 (N = 6) (%) 1 (N = 6) (%) 3 (N = 6) (%) 10 (N = 6) (%) Total (N = 36) (%)
Subjects with any TEAE 6 (75.0) 4 (66.7) 3 (50.0) 4 (66.7) 4 (66.7) 15 (62.5)
Upper respiratory tract infection 1 (12.5) 2 (33.3) 0 0 2 (33.3) 4 (16.7)
Headache 2 (25.0) 1 (16.7) 0 1 (16.7) 1 (16.7) 3 (12.5)
Orthostatic hypotension 0 1 (16.7) 0 2 (33.3) 0 3 (12.5)
Nausea 0 0 0 1 (16.7) 1 (16.7) 2 (8.3)
Procedural pain 0 1 (16.7) 0 0 1 (16.7) 2 (8.3)
Sinusitis 0 0 1 (16.7) 1 (16.7) 0 2 (8.3)
Somnolence 0 1 (16.7) 0 0 1 (16.7) 2 (8.3)
Urinary tract infection 0 0 0 1 (16.7) 1 (16.7) 2 (8.3)
Vomiting 0 0 0 0 2 (33.3) 2 (8.3)
For each row category, a subject with 2 or more TEAEs with the same PT in that category was counted only once. A TEAE is defined as an AE which started after
first dose and within 90 days of last dose.
AE adverse event, MAD multiple ascending dose, MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, SAD single ascending dose, TEAE
treatment emergent adverse event




(N = 12) (%) 0.1 (N = 6) (%) 0.3 (N = 6) (%) 1 (N = 6) (%) 3 (N = 6) (%) 10 (N = 6) (%) 15 (N = 6) (%) Total (N = 36) (%)
Subjects with any TEAE 8 (66.7) 6 (100.0) 1 (16.7) 3 (50.0) 3 (50.0) 2 (33.3) 5 (83.3) 20 (55.6)
Dizziness 1 (8.3) 2 (33.3) 0 1 (16.7) 0 0 0 3 (8.3)
Fatigue 1 (8.3) 0 0 0 0 0 2 (33.3) 2 (5.6)
Sinusitis 0 1 (16.7) 0 0 1 (16.7) 0 0 2 (5.6)
Asymptomatic ARIA-H 0 0 1 (16.7) 1 (16.7) 0 0 0 2 (5.6)
For each row category, a subject with 2 or more TEAEs with the same PT in that category was counted only once. A TEAE is defined as an AE which started after
first dose and within 90 days of last dose.
AE adverse event, MAD multiple ascending dose, MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, SAD single ascending dose, TEAE
treatment emergent adverse event
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Pharmacokinetics
SAD cohorts
Mean serum concentration time profiles of BAN2401 for
ascending doses are shown in Fig. 3a and findings for the
pharmacokinetic parameters are listed in Table 4. The me-
dian tmax occurred at approximately 1.8 to 2.2 h from the
start of infusion. The mean Cmax and the AUC increased ap-
proximately proportionally with BAN2401 dose from 0.3-
15 mg/kg. Single BAN2401 doses from 0.3-15 mg/kg
showed first order elimination kinetics. Due to limitations in
the assay, mean serum half-lives for BAN2401 were only es-
timated for subjects receiving 10 and 15 mg/kg of BAN2401
and were 165 h (6.9 days) and 174 h (7.3 days), respectively.
MAD cohorts
Mean serum concentration time profiles are shown in
Fig. 3a and b and findings for other pharmacokinetic
Fig. 3 a Pharmacokinetics of BAN2401, with mean serum concentration of BAN2401 in SAD cohorts. b Mean serum concentration of BAN2401
after the last dose in MAD cohorts of 0.3 – 3 mg/kg every 28 days (4 doses), or 10 mg/kg biweekly (7 doses). SAD single ascending dose, MAD
multiple ascending dose
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parameters are listed in Table 4. Overall, mean
Cmax and AUC values for the first dose of BAN2401
in each MAD cohort were consistent with corre-
sponding doses in the SAD cohorts. Mean Cmax and
AUC values of the first dose and the final dose in-
creased approximately dose proportionately from
0.3 mg/kg monthly to 10 mg/kg biweekly. The PK
profile during the elimination phase was consistent
with first-order kinetics. The mean half-life of
BAN2401 ranged from approximately 127 h (5.3 days)
after the final dose in the 10 mg/kg biweekly MAD
cohort, to 174 h (7.3 days) in the 15 mg/kg SAD
cohort.
As expected based on the half-life, no accumula-
tion was observed when BAN2401 was adminis-
tered at 28 day intervals. Biweekly infusions of
BAN2401 (10 mg/kg) achieved steady state serum
concentrations after the third dose, i.e., after ap-
proximately six weeks of treatment. The minimum
observed concentration at steady-state (Css, min)
achieved with this dosing regimen was approxi-
mately 40 μg/mL, with an accumulation factor of
approximately 1.4.
CSF: serum ratios
Concurrent concentrations of BAN2401 in serum and
CSF are shown in Table 5, together with the
CSF:serum ratios at 24 h and Day 10-14 after dosing.
Due to sampling error only two subjects in the
15 mg/kg SAD group had CSF concentrations mea-
sured on Day 10. One subject had a CSF concentra-
tion of 624 ng/mL (CSF: serum ratio 0.81 %) and the
other a CSF concentration of 72 ng/mL (CSF:serum
ratio 0.07 %). In the three lower dose MAD cohorts
in which there was no accumulation, the CSF:serum
ratios were 0.04 - 0.08 % at 24 h after the final dose
(Table 5). However, in the 10 mg/kg biweekly MAD
cohort there was BAN2401 accumulation in serum. In
this cohort, the CSF:serum ratio was 0.13 % at 24 h
after the final dose, and increased to 0.29 % at 14 days
after the final dose.
Target engagement and pharmacodynamics
BAN2401 was associated with small dose-dependent in-
creases in plasma Aβ(1-40) in the MAD cohorts within a
few hours after the first dose as well as the final dose
(Fig. 4, Table 6). Plasma Aβ(1-40) levels declined over
Table 4 Pharmacokinetic parameters of BAN2401
Cohort n Dose (mg/kg) Cmax (μg/mL) AUC(0-24) (μg*h/mL) AUC(0-inf) (μg*h/mL) t1/2 (h)
SAD1 6 0.1 NC NC NC NC
SAD2 6 0.3 8.50 (2.4) NC NC NC
SAD3 6 1 24.7 (3.6) NC NC NC
SAD4 6 3 74.2 (11) 1390 (140) 7430 (1210) NC
SAD5 6 10 264 (32.4) 5010 (550) 38000 (7340) 165 (45.5)
SAD6 6 15 418 (54.5) 7630 (593) 66900 (17600) 174 (36.1)
MAD1 6 0.3 7.26 (1.5) 133 (23) NA NC
MAD2 3 1 30.6 (4.6) 470 (110) NA NC
MAD3 5 3 68.8 (9) 1220 (132) NA NC
MAD4 6 10 307 (70.2) 5720(1230) NA 127(30)
PK parameters for the MAD cohorts were calculated after the final dose of BAN2401. Values reported are Mean (SD)
AUC area under the curve, NC not calculated due to insufficient data, NA not applicable for dosing with multiple doses.
Table 5 CSF and corresponding serum concentrations and CSF: serum ratios
BAN2401 levels 24 h after final dose BAN2401 levels 10-14 days after final dose
Cohort (dose mg/kg) CSF (ng/mL) Serum (μg/mL) CSF:serum Ratio CSF (ng/mL) Serum (μg/mL) CSF:serum ratio
SAD6 (15) 96.3 (45.1) 265 (63.1) 0.04 % (0.03 %) 72.2, 624a 104 (31.3) 0.07 %, 0.81%a
MAD1 (0.3) 3.47 (2.1) 4.85 (1.3) 0.08 % (0.05 %) CSF not collected
MAD2 (1) 8.89 (5.31) 17.6 (1.05) 0.04 % (0.03 %)
MAD3 (3) 25.0 (13.3) 44.1 (4.55) 0.06 % (0.04 %)
MAD4 (10) 263 (106) 211 (46.0) 0.13 % (0.03 %) 116 (109) 37.5 (21.8) 0.29 % (0.14 %)
Values are expressed as mean and (SD)
CSF cerebrospinal fluid, SAD single ascending dose, MAD multiple ascending dose
aIndividual values are shown because n = 2
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time with the fall in serum concentration of BAN2401.
However, there were no clear effects of BAN2401 on
CSF Aβ(1-42), t-tau, or p-tau (data not presented) com-
pared with placebo in the MAD cohorts.
Discussion
Bapineuzumab and other early Aβ immunotherapy pro-
grams have encountered safety issues mainly due to
ARIA-Es. A beneficial safety profile allowing for effica-
cious dose levels without undesired side effects is pivotal
for success. Safety and tolerability were the primary out-
come measures in this first-in-human study with
BAN2401 in subjects with mild-to-moderate AD. In this
study, BAN2401 was safe and well-tolerated at all doses
tested. The maximum tolerated dose was not reached
with either single or multiple dosing.
Asymptomatic ARIA-H occurred in 3/60 (5 %) sub-
jects treated with BAN2401, which is a lower inci-
dence than that observed in subjects treated with
placebo (2/20, 10 %). The incidence of ARIA in both
placebo and BAN2401 treatment groups at base-line
was within the expected levels [16]. For the ongoing
phase 2b study there were no dosing limitations based
on safety, as all doses were safe and tolerable.
Results of the non-compartmentalized PK analyses
indicate that BAN2401 is characterized by linear PK,
with dose-proportional exposure and first order
elimination. The mean serum half-life of BAN2401
was approximately seven days, which was reliably de-
termined when given at doses of 10 mg/kg or higher.
This was shorter than predicted from animal PK
studies. Consequently, a more frequent biweekly dos-
ing interval was considered important, and an add-
itional MAD cohort with 10 mg/kg biweekly dosing
was added. The 10 mg/kg biweekly dose achieved
minimum steady state levels of approximately 40 μg/mL
after three doses, with an accumulation factor of ap-
proximately 1.4. The PK profile has guided us for
selecting dose and dose regimens in the ongoing
phase 2b study.
BAN2401 penetrated the blood-brain barrier and
could be measured in CSF as a surrogate for CNS expos-
ure. Due to the limited numbers of CSF samples, a cau-
tious interpretation of the data is necessary. CSF
concentration 24 h after a single dose was 0.04 % of its
serum concentration and after monthly multiple doses
0.04 - 0.08 %, but was somewhat higher, 0.13 % at 24 h
post dose at steady state after biweekly dosing. Over a
14-day interval at steady state with multiple dosing at
10 mg/kg biweekly, the CSF: serum ratio increased to
0.29 %, which may suggest a longer half-life in CSF vs.
plasma.
Fig. 4 Mean concentrations of Aβ(1-40) versus nominal time for SAD cohorts. Aβ amyloid β, SAD single ascending dose
Table 6 Plasma pharmacodynamics in MAD cohort
Placebo MAD2 MAD3 MAD4
Plasma Aβ(1-40) mean (SD) concentration (pg/mL)
Maximal % change from baseline -27.39 (48.98) 15.92 (97.17) 39.71 (17.91) 120.71 (53.21)
24 h post final dose 13.42 (28.09) 16.99a 17.50 (9.14) 86.20 (48.06)
Percentage change from baseline in Aβ (1-40)
Aβ amyloid β, MAD multiple ascending dose
aInsufficient “n” to calculate SD
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There were no apparent effects of BAN2401 on CSF t-
tau, p-tau or Aβ(1-42). At present there is no validated
assay for measuring protofibrils in human CSF. Thus, it
was not possible to assess target engagement of
BAN2401 in CSF. However, ex vivo immunoprecipita-
tion experiments with BAN2401 demonstrated that the
antibody was able to pull-down virtually all Aβ(1-42) from
AD brain tissue in the fraction containing mainly soluble
Aβ aggregates. This indicates a high level of target en-
gagement in affected brains [17]. There was no clear
guidance for an effective dose based on biomarkers. For
this reason, several doses and dose regimens are being
tested in the ongoing phase 2b study. BAN2401 treat-
ment led to only a slightly increased plasma Aβ(1-40)
(Table 6), which was most evident at 10 mg/kg biweekly,
and this would be consistent with low affinity of
BAN2401 for monomeric Aβ present in human plasma.
Traditionally, SAD and MAD studies involve the com-
pletion of each cohort before proceeding to a higher
dose. In this study, we used a design allowing the SAD
and MAD cohorts to be intercalated and conducted in
staggered parallel fashion. Thus, the study duration was
significantly shortened. An adequate duration of follow
up for the assessment of ARIA and other potential ad-
verse events could still be ensured prior to initiation of
higher dose cohorts. In addition, PK results from com-
pleted earlier cohorts were used to amend the MAD
dose frequency to reflect the shorter than expected half-
life and to investigate if the PK profile in CSF might be
comparable to that in serum. Use of this innovative
study design enabled all cohorts to be completed within
12 months. It demonstrated that in this Phase 1 study
BAN2401 was safe and well-tolerated at single doses up
to 15 mg/kg and multiple doses up to 10 mg/kg bi-
weekly. On the basis of this study, a Phase 2b efficacy
study has been initiated in a combined population of
prodromal AD and mild AD dementia.
Conclusions
Several monoclonal antibodies for the treatment of AD
have been in development over the last decade.
BAN2401 is a monoclonal antibody that selectively binds
soluble Aβ protofibrils. The first clinical study described
in this paper demonstrates that that BAN2401 was safe
and well tolerated in mild to moderate AD. The pres-
ence of ARIA was assessed at multiple time points with
MRI. The incidence of ARIA on MRI was comparable to
that of placebo. BAN2401 exposure was approximately
dose proportional, with a serum terminal elimination
half-life of approximately seven days. Only a slight in-
crease of plasma Aβ(1-40) was observed but there were
no measurable effects of BAN2401 on CSF biomarkers.
On the basis of these findings, a Phase 2b efficacy study
has been initiated in early AD.
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